WG
MLYS icon

Winton Group’s Mineralys Therapeutics MLYS Stock Holding History

Winton Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$912K Buy
+33,800
New +$927K 0.03% 534
2026
Q1 		– Sell
-64,806
Closed -$2.35M – 1288
2025
Q4 		$2.35M Buy
+64,806
New +$2.6M 0.08% 282

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Winton Group's MLYS Position: Q2 2026 in Review

Winton Group opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 33,800 shares worth $912K. The stake represents 0.03% of the portfolio and ranks #534 among its holdings. This is a return to the name: Winton Group previously reported a position in MLYS as recently as Q4 2025.

Winton Group first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.35M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Winton Group held 33,800 shares of Mineralys Therapeutics worth $912K as of Q2 2026.
  • Mineralys Therapeutics was a new Winton Group position in Q2 2026.
  • Mineralys Therapeutics made up 0.03% of Winton Group's portfolio in Q2 2026, its #534 holding.
  • Winton Group first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Winton Group's Mineralys Therapeutics position peaked at $2.35M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.